Antimicrobial Agents and Chemotherapy

Journal Information
ISSN / EISSN : 0066-4804 / 1098-6596
Published by: American Society for Microbiology (10.1128)
Total articles ≅ 33,463
Current Coverage
SCOPUS
LOCKSS
MEDICUS
MEDLINE
PUBMED
PMC
SCIE
Archived in
SHERPA/ROMEO
Filter:

Latest articles in this journal

Fredrika Rajer, Lisa Allander, Philip A. Karlsson,
Antimicrobial Agents and Chemotherapy, Volume 66; https://doi.org/10.1128/aac.00290-22

Abstract:
β-Lactam antibiotics are the first choice for the treatment of most bacterial infections. However, the increased prevalence of β-lactamases, in particular extended-spectrum β-lactamases, in pathogenic bacteria has severely limited the possibility of using β-lactam treatments.
Adeline Supandy, Heer H. Mehta, , , Rutan Zhang, , Cesar A. Arias,
Antimicrobial Agents and Chemotherapy, Volume 66; https://doi.org/10.1128/aac.02333-21

Abstract:
Infections caused by vancomycin-resistant Enterococcus faecium (VREfm) are an important public health threat. VREfm isolates have become increasingly resistant to the front-line antibiotic daptomycin (DAP). As such, the use of DAP combination therapies with other antibiotics like fosfomycin (FOS) has received increased attention.
, Takashi Yaguchi, Mari Maeda, Mohamed Mahdi Alshahni, Karine Salamin, , ,
Antimicrobial Agents and Chemotherapy, Volume 66; https://doi.org/10.1128/aac.00059-22

Abstract:
Trichophyton indotineae causes dermatophytosis that is resistant to terbinafine and azole compounds. The aim of this study was to determine the mechanisms of resistance to itraconazole (ITC) and voriconazole (VRC) in strains of T. indotineae .
Tracy L. Diamond, Winnie Ngo, Min Xu, Shih Lin Goh, Silveria Rodriguez, Ming-Tain Lai, , Jay A. Grobler
Antimicrobial Agents and Chemotherapy, Volume 66; https://doi.org/10.1128/aac.00133-22

Abstract:
Islatravir (ISL) is a nucleoside reverse transcriptase translocation inhibitor (NRTTI) that inhibits human immunodeficiency virus (HIV) reverse transcription by blocking reverse transcriptase (RT) translocation on the primer:template. ISL is being developed for the treatment of HIV-1 infection.
Jonathan P. Huggins, Robert Pease, Kelly Stanly, Adrienne Workman, John Reynolds, Barbara D. Alexander
Antimicrobial Agents and Chemotherapy, Volume 66; https://doi.org/10.1128/aac.00283-22

Abstract:
Inhaled formulations of amphotericin B are the most widely used antifungal prophylactic agents in lung transplant recipients, yet there are limited data on their safety. We performed a single-center retrospective cohort study of 603 consecutive patients who underwent lung transplantation between 2012 and 2017 and received antifungal prophylaxis with inhaled amphotericin B lipid complex (iABLC) from the day of transplantation until hospital discharge.
Jillian E. Milanes, Jimmy Suryadi, Neil P. Monaghan, Elijah M. Harding, Corbin S. Morris, Soren D. Rozema, Muhammad M. Khalifa, , Isabelle Q. Phan, Rachael Zigweid, et al.
Antimicrobial Agents and Chemotherapy, Volume 66; https://doi.org/10.1128/aac.02373-21

Abstract:
Infection with pathogenic free-living amoebae, including Naegleria fowleri , Acanthamoeba spp., and Balamuthia mandrillaris , can lead to life-threatening illnesses, primarily because of catastrophic central nervous system involvement. Efficacious treatment options for these infections are lacking, and the mortality rate due to infection is high.
Emma C. Phillips, Cirle A. Warren, Jennie Z. Ma,
Antimicrobial Agents and Chemotherapy, Volume 66; https://doi.org/10.1128/aac.00001-22

Abstract:
This case series and propensity-matched cohort study on the use of tigecycline in Clostridioides difficile infection (CDI) evaluated the effect of tigecycline on 30-day mortality. Adjusted for ATLAS Score, hypotension, treatment time period, and serum lactate, tigecycline did not significantly improve 30-day mortality (odds ratio: 0.89; 95% confidence interval: 0.25–3.12; P =  0.853).
Aida N. Kawuma, Roeland E. Wasmann, , Marta Boffito, ,
Antimicrobial Agents and Chemotherapy, Volume 66; https://doi.org/10.1128/aac.00215-22

Abstract:
Dolutegravir-based regimens are recommended as first-line therapy for HIV in low- and middle-income countries where tuberculosis is the most common opportunistic infection. Concurrent HIV/tuberculosis treatment is challenging because of drug-drug interactions.
Kerstin Walter, Julia Kokesch-Himmelreich, Axel Treu, Franziska Waldow, Doris Hillemann, Nikolas Jakobs, Ann-Kathrin Lemm, Dominik Schwudke, Andreas Römpp,
Antimicrobial Agents and Chemotherapy, Volume 66; https://doi.org/10.1128/aac.01588-21

Abstract:
The Mycobacterium tuberculosis (Mtb)-harboring granuloma with a necrotic center surrounded by a fibrous capsule is the hallmark of tuberculosis (TB). For a successful treatment, antibiotics need to penetrate these complex structures to reach their bacterial targets. Hence, animal models reflecting the pulmonary pathology of TB patients are of particular importance to improve the pre-clinical validation of novel drug candidates. Mtb-infected interleukin-13 overexpressing (IL-13tg) mice develop a TB pathology very similar to patients and, in contrast to other mouse models, also share pathogenetic mechanisms. Accordingly, IL-13tg animals represent an ideal model for analyzing the penetration of novel anti-TB drugs into various compartments of necrotic granulomas by matrix-assisted-laser-desorption/ionization-mass spectrometry imaging (MALDI MS imaging). In the present study, we evaluated the suitability of BALB/c IL-13tg mice for determining the antibiotic distribution within necrotizing lesions. To this end, we established a workflow based on the inactivation of Mtb by gamma irradiation while preserving lung tissue integrity and drug distribution, which is essential for correlating drug penetration with lesion pathology. MALDI MS imaging analysis of clofazimine, pyrazinamide and rifampicin revealed a drug-specific distribution within different lesion types including cellular granulomas, developing in BALB/c wild-type mice, and necrotic granulomas of BALB/c IL-13tg animals, emphasizing the necessity of pre-clinical models reflecting human pathology. Most importantly, our study demonstrates that BALB/c IL-13tg mice recapitulate the penetration of antibiotics into human lesions. Therefore, our workflow in combination with the IL-13tg mouse model provides an improved and accelerated evaluation of novel anti-TB drugs and new regimens in the pre-clinical stage.
Back to Top Top